News
The complete response letter (CRL) specifies that the current dosage duration of aflibercept is still safe but extending the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback